Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

FDA Approves Pluvicto for Progressive, PSMA-Positive Metastatic CRPC

March 23rd 2022

The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.

Continuous Enzalutamide/Docetaxel May Represent Future Option for Select mCRPC Who Progress on Enzalutamide Alone

March 22nd 2022

Axel S. Merseburger, MD, discusses the safety and efficacy results from the phase 3b PRESIDE trial examining continued enzalutamide treatment with docetaxel in select patients with metastatic castration-resistant prostate cancer who had progressed on enzalutamide monotherapy and the significance of the data for the treatment paradigm.

Radiotherapy Treatments Are Getting Shorter and Faster in Prostate Cancer

March 17th 2022

The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.

Dr. Tagawa on Utilizing Bone-Targeting Radium-223 in Prostate Cancer

March 16th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

Dr. Dreicer on the Impact of the CHAARTED Trial in mCSPC

March 16th 2022

Robert Dreicer, MD, discusses the impact of the phase 3 CHAARTED trial in metastatic castration-sensitive prostate cancer.

Precision Medicine Takes Hold of Prostate Cancer Management

March 16th 2022

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

March 16th 2022

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

Phase 3 KEYLYNK-010 Trial Examining Pembrolizumab/Olaparib in mCRPC to Stop for Futility

March 15th 2022

The phase 3 KEYLYNK-001 trial evaluating the combination of pembrolizumab and olaparib in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate or enzalutamide will be discontinued for futility.

ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer

March 15th 2022

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

Patient-Reported Outcomes and Changes in PSA in Patients With Advanced Prostate Cancer Treated With Apalutamide in the SPARTAN and TITAN Studies

March 15th 2022

Expert urologist Benjamin Lowentritt, MD, reviews advanced prostate cancer data from the SPARTAN and TITAN studies comparing patient-reported outcomes to changes in PSA.

FDA and EMA Approval Sought for Darolutamide Plus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

March 9th 2022

A supplemental new drug application and a Variation Type II application have been submitted to the FDA and the European Medicines Agency, respectively, seeking the approval of darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Niraparib Plus Abiraterone Acetate/Prednisone Shows Potential as Frontline Option for HRR Gene–Altered mCRPC

March 9th 2022

Eleni Efstathiou, MD, PhD, discussed the combination of niraparib and abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations, results from the MAGNITUDE trial, and next steps for research.

Attainment of Early, Deep Prostate-Specific Antigen Response in mCSPC: A Comparison of Patients Initiated on Apalutamide or Enzalutamide

March 8th 2022

Expert urologist Benjamin Lowentritt, MD, reviews trial data comparing PsA response achieved with apalutamide versus enzalutamide in patients with castration-sensitive prostate cancer.

Rapid Readout: ARASENS: Darolutamide Versus Placebo in Combination With ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

March 7th 2022

Alan H. Bryce, MD, discusses the ARASENS trial, as presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium in February 2022.

PAGln in Gut Microbiome Represents Potential Link to Lethal Prostate Cancer

February 25th 2022

Nima Sharifi, MD, PLCO, discusses the results of the prostate cancer cohort in the PLCO trial and how PAGln could be linked to patients eventually diagnosed with lethal prostate cancer.

Bavdegalutamide Showcases Early Activity in Metastatic Castration-Resistant Prostate Cancer

February 24th 2022

The novel androgen receptor PROTAC degrader, bavdegalutamide, was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer.

Niraparib Demonstrates Antitumor Activity in Heavily Pretreated mCRPC With BRCA Mutations

February 23rd 2022

The PARP inhibitor niraparib elicited a meaningful overall response rate in patients with heavily pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, particularly those with BRCA alterations.

Dr. Lowentritt on a Real-World Analysis of Apalutamide and Enzalutamide in mCSPC

February 23rd 2022

Benjamin H. Lowentritt, MD, FACS, discusses the real-world analysis of apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer.

Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses

February 18th 2022

Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.

18F-rhPSMA-7.3 Imaging Favorable Detection Rates in Men with Recurrent Prostate Cancer

February 18th 2022

The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate.